Literature DB >> 11675419

Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension.

Inge H H T Klein1, Gerry Ligtenberg1, P Liam Oey2, Hein A Koomans1, Peter J Blankestijn1.   

Abstract

Hypertension is common in patients with polycystic kidney disease (PKD). This study addresses the hypothesis that sympathetic activity is enhanced in hypertensive PKD patients, not only when renal function is impaired but also when renal function is still normal. Muscle sympathetic nerve activity (MSNA, peroneal nerve), plasma renin activity (PRA), heart rate, and BP were studied in PKD patients with normal and with impaired renal function and in matched controls. In hypertensive patients with normal renal function, MSNA and mean arterial pressure (MAP) were higher than in normotensive patients (23 +/- 5 versus 15 +/- 7 bursts/min; 110 +/- 10 versus 90 +/- 3 mmHg; P < 0.05), whereas PRA and heart rate did not differ. In PKD with chronic renal failure (CRF) (creatinine clearance rate, 39 +/- 19 ml/min), MAP, MSNA and PRA were higher than in controls (resp, 116 +/- 7 versus 89 +/- 9 mmHg; 34 +/- 14 versus 19 +/- 9 bursts/min; 405 [20 to 1640] versus 120 [40 to 730] fmol/L per sec; all P < 0.05). Heart rate in PKD CRF did not differ from controls. MSNA correlated with MAP (r = 0.42; P = 0.01) and age with MSNA (r = 0.45; P < 0.01). Regression line of age and MSNA in patients was steeper than that in controls. This study indicates that MSNA is increased in hypertensive PKD patients regardless of renal function. The data support the idea that sympathetic hyperactivity contributes to the pathogenesis of hypertension in PKD.

Entities:  

Mesh:

Year:  2001        PMID: 11675419     DOI: 10.1681/ASN.V12112427

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  49 in total

1.  Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Authors:  Shobha Ratnam; Surya M Nauli
Journal:  Int J Nephrol Urol       Date:  2010

2.  Minor renal dysfunction: an emerging independent cardiovascular risk factor.

Authors:  E Ritz
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

Review 3.  Compelling drug indications in diabetic and nondiabetic nephropathy.

Authors:  Eberhard Ritz; Ralf Dikow; Martin Zeier
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

Review 4.  Premise, promise, and potential limitations of invasive devices to treat hypertension.

Authors:  Elizabeth A Martin; Ronald G Victor
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

Review 5.  Renal protection in hypertensive patients: selection of antihypertensive therapy.

Authors:  René R Wenzel
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Intra-operative inferior vena cava syndrome in a patient with autosomal dominant polycystic kidney disease.

Authors:  S A Pierre; M T Jaeger; D R Siemens
Journal:  World J Urol       Date:  2006-01-25       Impact factor: 4.226

Review 7.  The role of the kidney in regulating arterial blood pressure.

Authors:  Hani M Wadei; Stephen C Textor
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

Review 8.  Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options.

Authors:  Eva E Vink; Rosa L de Jager; Peter J Blankestijn
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

9.  Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.

Authors:  Guido Grassi; Gino Seravalle; Lorenzo Ghiadoni; Giovanni Tripepi; Rosa Maria Bruno; Giuseppe Mancia; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

Review 10.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.